← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors
olokizumab
L04AC23
Forms & Strengths
- Solution for injection: 45 mg/0.5 mL, 90 mg/1 mL in single-dose prefilled syringes or autoinjectors
Adult Dosing
- Subcutaneous injection: 64-128 mg at week 0, week 1 or 2, and every 4 weeks thereafter
- Administered via subcutaneous injection in the abdomen, thigh, or upper arm
Pediatric Dosing
- Not established for patients younger than 18 years
Indications
- Moderate to severe rheumatoid arthritis in adults who have had an inadequate response or are intolerant to one or more disease-modifying antirheumatic drugs
- Treatment of active psoriatic arthritis in adults
Mechanism of Action
- Humanized monoclonal antibody that selectively binds to the interleukin-6 (IL-6) cytokine, blocking its signaling through membrane-bound and soluble IL-6 receptors
- Inhibits IL-6-mediated signaling, which plays a key role in inflammation and the autoimmune response
Contraindications
- Serious infections, including sepsis, opportunistic infections, or active tuberculosis
- Hypersensitivity to olokizumab or any component of the formulation
Adverse Reactions
- Upper respiratory tract infections
- Headache
- Influenza
- Neutropenia
- Hypertension
- Elevations in liver enzymes
Drug Interactions
- Concomitant use with biologic disease-modifying antirheumatic drugs: increased risk of infections
- Concomitant use with immunosuppressants: increased risk of infections and potentially lymphomas
- Concomitant use with live vaccines: not recommended due to risk of vaccine-related infections
Curated Content: Needs Vetting Before Put to Clinical Use